SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its resilient development team and utility-focused roadmap, highlighting staking opportunities and the Broke Perspective media platform. Despite market dips, the community expresses conviction, emphasizing long-term building and the potential for significant gains. Discussions also involve collaborations and support from other Solana-based projects.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

MUSE

MUSE is trending as traders discuss its limited coin supply and potential for a squeeze, drawing comparisons to past rallies and other low-cap cryptos. Community members are actively watching volume, speculating on price movements, and highlighting its potential within the NFT space. Some believe that with increased exposure, MUSE could see significant gains.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its narrative of disrupting traditional retirement plans, with many expressing bullish sentiment and highlighting the project's strong community and organic growth on the $SOL blockchain. Discussions revolve around the token's potential to reach new all-time highs and offer an alternative path to financial freedom, contrasting it with perceived flaws in the traditional 401(k) system. The community is actively promoting its message and celebrating milestones, with a focus on long-term vision rather than short-term gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson &amp; Johnson’s (J&amp;J) stock&nbsp;fell 0.4% in premarket trade on Tuesday as investors positioned ahead of the healthcare giant’s quarterly results due Tuesday, with focus on its medical devices business, drug pipeline, and tariff exposure.The company is expected to post revenue of $23.76 billion, nearly flat from last year's $23.74 billion, according to estimates from Koyfin. Adjusted EPS is expected to be $2.76, down from $2.77 a year ago. EBITDA is expected to come in 0.6% lower at $8.58 billion, while EBIT is expected to tick up 0.5% to $8 billion.J&amp;J shares trade near $190.90, close to their 12-month average price target of $187.49, implying limited near-term upside. Analysts maintain a broadly positive stance, with 10 rating it a ‘Buy,’ 11 a ‘Hold,’ and two a ‘Strong Buy.’In July, J&amp;J cut its tariff-related cost forecast for the year to $200 million, down from $400 million, citing lower-than-expected impact on its medical devices business after the Trump administration paused some China and EU duties. CFO Joe Wolk said the company absorbed the costs while still raising its profit outlook, describing the tariff effect as “minimal.”Growth in the medtech unit is expected to be a bright spot, driven by sales from cardiovascular products such as Varipulse and Trupulse, and Abiomed’s Impella heart pumps. J&amp;J said in July that robotic surgery and cardiovascular devices will be the key engines of growth for its medtech unit.Attention will also be on Carvykti, J&amp;J’s blood cancer therapy developed with Legend Biotech, which recently received a U.S. FDA label update adding a black box warning for a rare intestinal inflammation. Regulators said the therapy’s benefits still outweigh risks, highlighting longer patient survival versus standard treatments.In immunology, the company faces renewed pressure from biosimilar competition to its top-selling drug Stelara. To offset potential declines, J&amp;J has been pursuing acquisitions, including reported talks to acquire Protagonist Therapeutics, its partner on an oral therapy for plaque psoriasis and ulcerative colitis. A deal would add late-stage drug Rusfertide, seen as complementary to J&amp;J’s immunology and oncology portfolios.Legal overhangs persist after a $966 million jury verdict in California earlier this month tied to talc-related cancer claims, which J&amp;J plans to appeal. The company maintains&nbsp;that its products are safe and asbestos-free.On Stocktwits, retail sentiment for J&amp;J was ‘extremely bullish’ amid a&nbsp; 2,200% surge in 24-hour message volume.One user predicted that J&amp;J shares could climb to the $196–$200 range after earnings, while others speculated the biotech might announce an Altimmune acquisition during Tuesday’s earnings call.<stembedurl>https://stocktwits.com/Wenwenwenwenwenwen/message/632192878</stembedurl><stembedurl>https://stocktwits.com/Ad7777/message/632156784</stembedurl><stembedurl>https://stocktwits.com/namv/message/632137184</stembedurl><a href="https://stocktwits.com/symbol/JNJ">J&amp;J’s stock</a> has risen 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

JNJ beat third-quarter earnings estimates but lowered guidance for the year 

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Equity

BMO Capital raised its price target on Protagonist Therapeutics to $112 from $72 and maintained an 'Outperform' rating, citing reports that Johnson &amp; Johnson may acquire the biotech firm.&nbsp;In a note to investors, the firm said its updated model better reflects the potential value of Protagonist’s two key drug assets, Rusfertide and Icotrokinra, for an acquirer, and that the market is “underpricing what Protagonist could be worth.”<a href="https://stocktwits.com/symbol/PTGX">Protagonist Therapeutics’ stock</a> fell 9% to $79.17 on Monday, marking its worst trading session in more than three months, before edging up 0.1% in after-hours trade.J&amp;J is reportedly in talks to buy Protagonist in a deal that would strengthen its existing partnership on an oral therapy for immune diseases such as plaque psoriasis and ulcerative colitis, for which J&amp;J already holds exclusive commercialization rights. The healthcare giant also owns nearly 4% of Protagonist’s shares, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d">reported</a> last week.An acquisition would give J&amp;J access to Rusfertide, which has shown promise in late-stage trials for polycythemia vera, a rare blood cancer. Both Rusfertide and Icotrokinra would complement J&amp;J’s existing portfolio of immune and oncology treatments.Meanwhile, J&amp;J is seeking acquisitions to offset declining sales of its blockbuster immune-disease drug Stelara, now facing biosimilar competition.On Stocktwits, retail sentiment was ‘bullish’ for Protagonist Therapeutics with ‘extremely high’ message volume, while sentiment toward Johnson &amp; Johnson was ‘extremely bullish’ amid normal activity.One user called the pullback in Protagonist a “great buying opportunity,” arguing that retail investors were mistaken to think the company would sell for less than $5 billion.&nbsp;<stembedurl>https://stocktwits.com/outlawinvestor1/message/632143522</stembedurl>On the other hand, another user predicted the potential deal could value Protagonist shares&nbsp;at around $35.<stembedurl>https://stocktwits.com/Fugazi_/message/632134508</stembedurl>So far this year, Protagonist shares have more than doubled in value, while&nbsp;<a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson shares</a> have gained about 35%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, Protagonist shares (PTGX) have more than doubled in value, while Johnson & Johnson shares (JNJ) have gained about 35%. (Photo credit: Getty Images)

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

The research firm said its higher target better reflects the value of Protagonist’s key drug assets, Rusfertide and Icotrokinra.

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.

RTW Investments' Rod Wong: Expect more deals in biotech space

Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the...

JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra

J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Protagonist Therapeutics Set to Join S&P SmallCap 600

Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK, June 27, 2024 NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTGX News

PTGXProtagonist Therapeutics Inc